Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05418582 · ClinicalTrials.gov registry record · Phase 1
Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine
A Phase 1 study, sponsored by Dizal Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT05418582 is a Phase 1 study that has completed, run by Dizal Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT05418582, a Phase 1 study, has completed, sponsored by Dizal Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This is a Phase 1, single-center, nonrandomized, open-label, 2-part, fixed-sequence, drug-drug interaction (DDI) study to assess the effect of multiple doses of itraconazole, a CYP3A4 enzyme inhibitor, on the single dose PK of DZD9008 in healthy adult subjects (Part A) and to assess the effect of multiple doses of carbamazepine, a CYP3A4 inducer, on the single dose PK of DZD9008 in healthy adult subjects (Part B).
Interventions
- DRUG DZD9008 and intraconazole
- DRUG DZD9008 and carbamazepine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-01-25 |
| Est. Completion | 2022-12-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05418582
The ClinicalTrials.gov registry entry for NCT05418582 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dizal Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DZD9008 and intraconazole is the first listed.
NCT05418582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05418582 about?
NCT05418582 is a clinical study titled "Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine". This is a Phase 1, single-center, nonrandomized, open-label, 2-part, fixed-sequence, drug-drug interaction (DDI) study to assess the effect of multiple doses of itraconazole, a CYP3A4 enzyme inhibitor, on the single dose PK of DZD9008 in healthy adult subjects (Part A) and to assess the effect of mu...
What is the current status of trial NCT05418582?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2022-01-25. Estimated completion is 2022-12-08.
What interventions are being tested in trial NCT05418582?
The interventions under investigation include: DZD9008 and intraconazole (DRUG), DZD9008 and carbamazepine (DRUG).
Who is sponsoring clinical trial NCT05418582?
This trial is sponsored by Dizal Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.